North America Migraine Treatment Market – Industry Trends and Forecast to 2027

  • Healthcare
  • Published Report
  • Jun 2020
  • North America
  • 350 Pages
  • No of Tables: 169
  • No of Figures: 49

North America Migraine Treatment Market, By Types of Migraine (Episodic, Migraine with Aura,  Chronic and Others), Treatment (Acute/Abortive Treatment, Preventive/Prophylactic Treatment, Non-Pharmacological Therapies and Devices), Route of Administration (Oral, Parenteral, Nasal Sprays and Others), Product Type (Prescription and Over The Counter), Type (Branded and  Generic) End User (Hospitals, Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies And Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2027    

North America Migraine Treatment MarketMarket Analysis and Insights: North America Migraine Treatment Market  

Migraine treatment market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 11.8% in the forecast period of 2020 to 2027 and expected to reach USD 7,245.38 million by 2027. Rising prevalence of migraine and development of novel drugs, are the major drivers which propelled the demand of the market in the forecast period.

Migraine treatment comprises features such as technological advancement for the treatment of acute migraine will impact in launching new product by the manufactures into the market which enhance its demand as well as rising collaborations, and merger & acquisitions among the market players has enhanced the demand of migraine  treatment. Currently various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and innovative and advanced migraine treatment drugs which expected to provide various other opportunities in the migraine treatment market. However, recall of drugs and adverse effects of drugs expected to restraint the market growth in the forecast period.   

The migraine treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.  

North America Migraine Treatment MarketMigraine Treatment Market Scope and Market Size

Migraine treatment market is segmented on the basis of types of migraine, treatment, route of administration, product type, type, end user and distribution channel. The growth among segments helps you to analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets. 

  • On the basis of types of migraine, the market is segmented into episodic, chronic, migraine with aura and others. Episodic segment is expected to dominate the market as it is most prevalent migraine form as well as volume of treatment of episodic migraine is higher as compared to other type of migraine.
  • On the basis of treatment, the market is segmented into acute/abortive treatment, preventive/prophylactic treatment, non-pharmacological therapies and devices. Acute/abortive treatment is expected to dominate the market as so many advancement has been seen in acute/abortive treatment as compared to that of the preventive/prophylactic treatment, non-pharmacological therapies and devices.
  • On the basis of route of administration, the market is segmented into oral, parenteral, nasal sprays and others. Oral segment is expected to dominate the market due to availability of large number of drugs which administered by oral route and are considered as first line of therapy with high effectiveness.
  • On the basis of product type, the market is segmented into prescription and over the counter. Prescription segment is expected to dominate the market as majority of migraine treatment drugs such as CGRP antagonists, calcium channel blockers, beta-blockers, and others are available only on prescription basis.
  • On the basis of type, the market is segmented into branded and generic. Generic segment is expected to dominate the market due to low cost of generic drugs as well as the subsequent support by the government across different countries of the world.
  • On the basis of end user, the market is segmented into hospitals, clinics, homecare and others. Hospital segment is expected to dominate the market as based on the severity of the migraine attack, patients are admitted to hospital for aggressive treatment, along with this the other factor favouring the dominance of hospital is number of hospitals which are more as compared to that of clinics and homecare.
  • On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others. Hospital pharmacies segment is expected to dominate the market as most of the patients who visit hospitals for the migraine treatment feel convenient to purchase drugs from the hospital pharmacy.

Migraine Treatment Market Country Level Analysis

The migraine treatment market is analysed and market size information is provided by type of migraine, treatment, route of administration, product type, type, end user and distribution channel.

The countries covered in migraine treatment market report are the U.S., Canada and Mexico in the North America. 

The U.S. is dominating the North America migraine treatment market because of large number of companies operating in the market along with increasing focus of authorities on migraine as a major disability hampering the optimum economic growth of the country. Moreover, the launch of novel drugs in the country makes it an important market for branded drugs as well.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, launch of new drugs, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Availability of Large Number of Generic Drugs is propelling the Market Growth

Migraine treatment market also provides you with detailed market analysis for every country growth in migraine treatment industry with migraine treatment sales, impact of advancement in the migraine treatment and changes in regulatory scenarios with their support for the migraine treatment market. The data is available for historic period 2010 to 2018. 

Competitive Landscape and Migraine Treatment Market Share Analysis

Migraine treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to migraine treatment market.

The major players covered in the report are Eli Lilly and Company, AstraZeneca, Amgen Inc., Allergan, Pfizer Inc., GlaxoSmithKline plc., Biohaven Pharmaceuticals, Teva Pharmaceuticals USA, Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd), Bausch Health Companies Inc., Abbott, Dr. Reddy’s Laboratories Ltd., Lundbeck, Merck Sharp & Dohme Corp. (A Subsidiary of Merck& Co. Inc.), Novartis AG, Otsuka Pharmaceutical Co., Ltd (A Subsidiary of Otsuka Holdings Co., Ltd.), Catalent, Inc, Bayer AG, Sun Pharmaceutical Industries Ltd., Neurelis, Inc., Zosano Phamra Corporation, Impel NeuroPharma, Inc., among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launch, approval, partnership and agreement are also initiated by the companies’ worldwide which are also accelerating the migraine treatment market.

For instance,

  • In May 2018 Amgen Inc. received FDA approval for Aimovig, a product for the treatment of migraine in adults which acts by blocking the calcitonin gene-related peptide receptor (CGRP-R). This has helped the company to increase its product portfolio of migraine treatment globally.
  • In December 2019 Allergan received FDA approval for UBRELVY (ubrogepant) for the acute treatment of migraine. This is the first CGRP antagonist which can be administered orally. This product approval has helped the company to enhance its revenue by increasing product sale.

Collaboration, joint ventures and other strategies by the market player is enhancing the company market in the migraine treatment market which also provides the benefit for organisation to improve their offering for migraine treatment.

Customization Available: North America Migraine Treatment Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES

TABLE 1 GENERIC DRUGS FOR MIGRAINE TREATMENT

TABLE 2 PIPELINE DRUGS FOR MIGRAINE TREATMENT

TABLE 3 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY PIPELINE ANALYSIS

TABLE 4 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 5 NORTH AMERICA EPISODIC IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 6 NORTH AMERICA MIGRAINE WITH AURA IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 7 NORTH AMERICA CHRONIC IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 8 NORTH AMERICA OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 9 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 10 NORTH AMERICA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 11 NORTH AMERICA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 12 NORTH AMERICA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TRAETMENT, 2018-2027 (USD MILLION)

TABLE 13 NORTH AMERICA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 14 NORTH AMERICA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 15 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 16 NORTH AMERICA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 17 NORTH AMERICA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 18 NORTH AMERICA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 19 NORTH AMERICA OTHERS IN MIGRAINE TREATMENT MARKET, BY TRATMENT, 2018-2027 (USD MILLION)

TABLE 20 NORTH AMERICA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 21 NORTH AMERICA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 22 NORTH AMERICA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 23 NORTH AMERICA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 24 NORTH AMERICA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 25 NORTH AMERICA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 26 NORTH AMERICA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 27 NORTH AMERICA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 28 NORTH AMERICA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 29 NORTH AMERICA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 30 NORTH AMERICA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 31 NORTH AMERICA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 32 NORTH AMERICA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 33 NORTH AMERICA DEVICES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 34 NORTH AMERICA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 35 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 36 NORTH AMERICA ORAL IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 37 NORTH AMERICA PARENTERAL IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 38 NORTH AMERICA NASAL SPRAYS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 39 NORTH AMERICA OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 40 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 41 NORTH AMERICA PRESCRIPTION IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 42 NORTH AMERICA OVER THE COUNTER IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 43 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 44 NORTH AMERICA GENERIC IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 45 NORTH AMERICA BRANDED IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 46 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 47 NORTH AMERICA HOSPITALS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 48 NORTH AMERICA CLINICS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 49 NORTH AMERICA HOMECARE IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 50 NORTH AMERICA OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 51 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 52 NORTH AMERICA HOSPITAL PHARMACIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 53 NORTH AMERICA RETAIL PHARMACIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 54 NORTH AMERICA ONLINE PHARMACIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 55 NORTH AMERICA OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 56 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 57 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 58 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 59 NORTH AMERICA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 60 NORTH AMERICA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 61 NORTH AMERICA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 62 NORTH AMERICA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 63 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 64 NORTH AMERICA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 65 NORTH AMERICA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 66 NORTH AMERICA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 67 NORTH AMERICA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 68 NORTH AMERICA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 69 NORTH AMERICA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 70 NORTH AMERICA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 71 NORTH AMERICA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 72 NORTH AMERICA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 73 NORTH AMERICA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 74 NORTH AMERICA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 75 NORTH AMERICA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 76 NORTH AMERICA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 77 NORTH AMERICA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 78 NORTH AMERICA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 79 NORTH AMERICA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 80 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 81 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 82 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 83 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 84 NORTH AMERICA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 85 U.S. MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 86 U.S. MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 87 U.S. ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 88 U.S. NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 89 U.S. TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 90 U.S. OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 91 U.S. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 92 U.S. ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 93 U.S. ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 94 U.S. ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 95 U.S. OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 96 U.S. PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 97 U.S. ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 98 U.S. CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD)

TABLE 99 U.S. SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 100 U.S. ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 101 U.S. NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 102 U.S. BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 103 U.S. BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 104 U.S. CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 105 U.S. ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 106 U.S. NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 107 U.S. DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 108 U.S. MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 109 U.S. MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 110 U.S. MIGRAINE TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 111 U.S. MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 112 U.S. MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 113 CANADA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 114 CANADA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 115 CANADA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 116 CANADA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 117 CANADA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 118 CANADA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 119 CANADA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 120 CANADA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 121 CANADA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 122 CANADA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 123 CANADA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 124 CANADA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 125 CANADA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 126 CANADA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 127 CANADA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 128 CANADA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 129 CANADA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 130 CANADA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 131 CANADA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 132 CANADA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 133 CANADA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 134 CANADA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 135 CANADA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 136 CANADA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 137 CANADA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 138 CANADA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 139 CANADA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 140 CANADA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 141 MEXICO MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 142 MEXICO MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 143 MEXICO ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 144 MEXICO NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 145 MEXICO TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 146 MEXICO OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 147 MEXICO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 148 MEXICO ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 149 MEXICO ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 150 MEXICO ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 151 MEXICO OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 152 MEXICO PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 153 MEXICO ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 154 MEXICO CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 155 MEXICO SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 156 MEXICO ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 157 MEXICO NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 158 MEXICO BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 159 MEXICO BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 160 MEXICO CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 161 MEXICO ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 162 MEXICO NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 163 MEXICO DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 164 MEXICO MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 165 MEXICO MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 166 MEXICO MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 167 MEXICO MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 168 MEXICO MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 169 SUBSIDIARIES OF JANSSEN NORTH AMERICA SERVICES, LLC

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19